Please assess the completion status of the following clinical trial:

Trial Title: Sorafenib, Cisplatin, and Etoposide in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of extensive-stage small cell lung cancer~* No untreated brain metastases~  * No active symptoms related to brain metastases~PATIENT CHARACTERISTICS:~* ECOG performance status 0-2~* Hemoglobin ≥ 9.0 g/dL~* ANC ≥ 1,500/mm³~* Platelet count ≥ 100,000/mm³~* Total bilirubin ≤ 1.5 times upper limit of normal (ULN)~* ALT and AST ≤ 2.5 times ULN (≤ 5 times ULN for patients with liver involvement)~* Creatinine ≤ 1.5 times ULN~* INR \< 1.5 or PT/PTT normal~* No history of cardiac disease, including any of the following:~  * NYHA class III-IV congestive heart failure~ * Unstable angina (i.e., anginal symptoms at rest)~ * Onset of angina within the past 3 months~ * Myocardial infarction within the past 6 months~* No cardiac ventricular arrhythmias requiring anti-arrhythmic therapy~* No uncontrolled hypertension, defined as systolic blood pressure (BP) \> 150 mm Hg or diastolic BP \> 90 mm Hg, despite optimal medical management~* No thrombolic or embolic events, such as cerebrovascular accident or transient ischemic attacks, within the past 6 months~* No pulmonary hemorrhage/bleeding event ≥ CTCAE grade 2 within the past 4 weeks~* No other hemorrhage/bleeding event ≥ CTCAE grade 3 within the past 4 weeks~* No known HIV infection or chronic hepatitis B or C infection~* No active clinically serious infection \> CTCAE grade 2~* No serious non-healing wound, ulcer, or bone fracture~* No evidence or history of bleeding diathesis or coagulopathy~* No significant traumatic injury within the past 4 weeks~* No known or suspected allergy to sorafenib tosylate or to any other drug given during the study~* No condition that would impair the patient's ability to swallow whole pills~* No known malabsorption problem~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective barrier contraception~  * Male patients must use effective contraception during and for ≥ 3 months after completion of sorafenib tosylate~PRIOR CONCURRENT THERAPY:~* Prior radiotherapy to the brain allowed~* No prior chemotherapy~* More than 4 weeks since prior major surgery or open biopsy~* No concurrent Hypericum perforatum (St. John's wort) or rifampin~* Concurrent anti-coagulation treatment, such as warfarin or heparin, allowed

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sorafenib, Cisplatin, and Etoposide (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).